1 / 37

Papers #041-044 Discussion

Papers #041-044 Discussion. Paolo G. Casali paolo.casali@istitutotumori.mi.it. Potential conflicts of interest. Empl Cons Stocks Honor Res Test Other Amgen Dompé l l ARIAD l Bayer l l Glaxo SK l l ImClone l Infinity l Janssen Cilag l l Lilly l

kai-clayton
Télécharger la présentation

Papers #041-044 Discussion

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Papers #041-044 Discussion Paolo G. Casali paolo.casali@istitutotumori.mi.it

  2. Potential conflicts of interest Empl Cons Stocks Honor Res Test Other Amgen Dompé l l ARIAD l Bayer ll Glaxo SK l l ImClone l Infinity l Janssen Cilag l l Lilly l Merck SD ll Molmed l Novartis llll Pfizer lll PharmaMar llll Sanofi Aventis ll Schering Plough l

  3. J Clin Oncol 2001;19:197

  4. J Clin Oncol 2001;19:197

  5. Discrepant behaviors? • embryonal • group III • favorable site • after CR or NED after delayed surgery

  6. Solitary fibrous tumor

  7. Solitary fibrous tumor benign malignant dedifferentiated

  8. WHO 2013 • SFT • SFT, malignant • SFT, dedifferentiated

  9. «Principle of excluded middle»… «A ≠ non-A» Aristotle (384-322 BC)

  10. WHO 2013… • Benign • Locally aggressive non metastazizing • Rarely metastatizing • Malignant < 2%!

  11. Surgery: main sites • Pleura • Peritoneum • Soft tissues • Viscera • Meninges (incl.: retrobulbar, paravertebral, …) • …..

  12. Re-challenge… +10 cycles +9 cycles (23 overall) PD after stopping T (TTP from the end of T = 14 mos)

  13. Mol Cancer Therap 2009;8:449

  14. Oncogene 2013; in press

  15. Synovial sa t(X;18)(p11;q11) SS18-SSX1 SS18-SSX2 SS18-SSX4 Myxoid liposa t(12;16)(q13;p11) FUS-CHOP t(12;22)(q13;q12) EWS-CHOP Esk. myx. chondrosa t(9;22)(q22;q12) EWS-NR4A3 t(9;17)(q22;q11) RBP56-NR4A3 t(9;15)(q22;q21) TCF12-NR4A3 Fibromyxoid sa t(7;16)(q33;p11) FUS-CREB3L2 t(11;16)(p11;p11) FUS-CREB3L1 Clear cell sa t(12;22)(q13;q12) EWS-ATF1 Dermatofibrosa t(17;22)(q22;q13) COL1A1-PDGFB EFT t(11;22)(q24;q12) EWS-FL1 t(21;22)(q22;q12) EWS-ERG t(7;22)(p22;q12) EWS-ETV1 t(17;22)(q12;q12) EWS-E1AF t(2;22)(q33;q12) EWS-FEV Desmopl. SRCT t(11;22)(p13;q12) EWS-WT1 Alv. rhabdomyosa t(2;13)(q35;q14) PAX3-FOXO1A t(1;13)(p36;q14) PAX7-FOXO1A Alv. soft part sa t(X;17)(p11;q25) TFE3-ASPL Angiomatoid f. histiocytoma t(12;16)(q13;p11) FUS-ATF1 Cong fibrosa t(12;15)(p13;q25) ETV6-NTRK3 Endometrial stromal sa t(7;17)(p15;q21) JAZF1-JJAZ1 Infl. myofibro. t. t(1;2)(q22;p23) TPM3-ALK t(2;19)(p23;p13) TPM4-ALK t(2;17)(p23;q23) CLTC-ALK t(2;2)(p23;q13) RANBP2-ALK …..

  16. L-STS! leiomyosarcoma liposarcoma

  17. Paolo G. Casali paolo.casali@istitutotumori.mi.it

More Related